New virus markers could transform CMV care in transplant patients
NCT ID NCT07286461
First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study will enroll 290 adults who have had a stem cell transplant and are at risk for CMV infection. Researchers will measure different virus markers in the blood to see which ones best predict when CMV becomes active and when treatment is needed. The goal is to improve monitoring and guide doctors in using antiviral drugs more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Heinrich-Heine-Universitaet Duesseldorf
Düsseldorf, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.